Reference health
Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition
66/66 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
4 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 66 checked references that resolve
resolves10.1038/nrd4504
The history and future of targeting cyclin-dependent kinases in cancer therapy
resolves10.1158/1078-0432.CCR-16-0620
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
resolves10.1073/pnas.181342398
Electrostatics of nanosystems: Application to microtubules and the ribosome
resolves10.1016/S0092-8674(00)81065-X
Crystal Structure and Mutational Analysis of the Human CDK2 Kinase Complex with Cell Cycle–Regulatory Protein CksHs1
resolves10.1038/ncomms7769
CDK1 structures reveal conserved and unique features of the essential cell cycle CDK
resolves10.1038/15674
The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases
resolves10.1158/1535-7163.MCT-08-0836
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
resolves10.1021/acs.jmedchem.6b01254
Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines
resolves10.1016/j.bmcl.2013.11.041
Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor
resolves10.1016/j.bbapap.2009.10.002
Recent developments in cyclin-dependent kinase biochemical and structural studies
resolves10.1146/annurev-biochem-052410-090317
The Structural Basis for Control of Eukaryotic Protein Kinases
resolves10.1158/1078-0432.CCR-13-1337
Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in
<i>CCNE1</i>
-Amplified Ovarian Cancer
resolves10.1073/pnas.1314302110
Synthetic lethality between
<i>CCNE1</i>
amplification and loss of
<i>BRCA1</i>
resolves10.1158/1940-6207.CAPR-10-0297
Cyclin E Transgenic Mice: Discovery Tools for Lung Cancer Biology, Therapy, and Prevention
resolves10.1021/jm301495v
Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity
resolves10.1007/s00894-005-0028-4
AMBER force-field parameters for phosphorylated amino acids in different protonation states: phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidine
resolves10.1002/prot.21123
Comparison of multiple Amber force fields and development of improved protein backbone parameters
resolves10.1021/ci100275a
Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations
resolves10.1016/S0960-894X(98)00691-X
2,6,9-trisubstituted purines : Optimization towards highly potent and selective CDK1 inhibitors
resolves10.1038/376313a0
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex
resolves10.1016/j.ygyno.2016.07.111
Cyclin E as a potential therapeutic target in high grade serous ovarian cancer
resolves10.1016/j.ajpath.2016.02.024
Cytoplasmic Cyclin E and Phospho–Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer
resolves10.1158/1535-7163.TARG-13-PR02
Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.
resolves10.1016/0092-8674(91)90044-Y
Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family
resolves10.3390/molecules190914366
Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
resolves10.1021/cb4003283
Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
resolves10.1107/S0907444911007281
Presenting your structures: the<i>CCP</i>4<i>mg</i>molecular-graphics software
resolves10.1016/j.molcel.2008.10.022
Distinct Activation Pathways Confer Cyclin-Binding Specificity on Cdk1 and Cdk2 in Human Cells
resolves10.1107/S0907444911001314
<i>REFMAC</i>5 for the refinement of macromolecular crystal structures
resolves10.1158/1535-7163.MCT-10-0324
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
resolves10.1006/jmbi.1999.2640
Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and cip and INK4 inhibitors
resolves10.1107/S2059798317016035
<i>CCP</i>4<i>i</i>2: the new graphical user interface to the<i>CCP</i>4 program suite
resolves10.1038/nsb0896-696
Structural basis of cyclin-dependent kinase activation by phosphorylation
resolves10.1021/jm301475f
Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities
resolves10.2174/092986710790514453
Towards Accurate Free Energy Calculations in Ligand Protein-Binding Studies
resolves10.1038/srep08457
Revealing the favorable dissociation pathway of type II kinase inhibitors via enhanced sampling simulations and two-end-state calculations
resolves10.1021/jm049354h
Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6
resolves10.1007/s11523-017-0541-2
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
resolves10.1016/j.jmgm.2005.12.005
Automatic atom type and bond type perception in molecular mechanical calculations
resolves10.1074/jbc.M609151200
How Tyrosine 15 Phosphorylation Inhibits the Activity of Cyclin-dependent Kinase 2-Cyclin A
resolves10.1016/j.pharmthera.2017.02.008
Inhibitors of cyclin-dependent kinases as cancer therapeutics
The 4 references without a DOI — listed, not checked
no DOI — not checkedFlavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
no DOI — not checkedA novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells
no DOI — not checked10.1016/j.chembiol.2018.10.015_bib50
no DOI — not checked10.1016/j.chembiol.2018.10.015_bib67
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.chembiol.2018.10.015"><img src="https://citestamp.com/citestamped/10.1016/j.chembiol.2018.10.015/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.chembiol.2018.10.015)